Following further investigation, the team found that EZH2 inhibitors increased the expression of MAD2L2 and rendered HR‐proficient epithelial ovarian cancer (EOC) sensitive to poly (adenosine diphosphate‐ribose) polymerase (PARP) inhibitors, dependent on CARM1. This evidence concerns the gene EZH2 and malignant epithelial tumor of ovary.